DeCure for Ehlers-Danlos syndrome, arthrochalasia type
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Ehlers-Danlos syndrome, arthrochalasia type — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleEhlers-Danlos syndrome, arthrochalasia type maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for ehlers-danlos syndrome, arthrochalasia type is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
albumin (ALB) — ALB is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet myrdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8RCO · 1.9 Å · ligand MYRISTIC ACID (MYR). Experimental structure, not a prediction.
What the evidence adds up to
No drug treatment is described in any of these abstracts for Ehlers-Danlos syndrome arthrochalasia type. The condition is caused by mutations in COL1A1 or COL1A2 that lead to skipping of exon 6 and defective collagen synthesis. Only about 42 cases have been published worldwide. The 2011 report describes seven patients at different ages, with timing of diagnosis ranging from prenatal life to adulthood, and notes that achieving mobility is the greatest challenge and may be impossible because of recurrent dislocations of nearly all joints in severe cases. The 2022 systematic review analysed 20 articles and states there is no curative treatment. The 2022 case report of an 8-year-old child born to first-cousin parents likewise states there is no curative treatment.
All three sources agree that management is symptomatic and focuses on quality of life. The systematic review specifies that treatment is currently symptomatic with no curative treatment available. The case report emphasises the importance of early diagnosis for optimal symptomatic management and prevention of avoidable complications. No intervention tested in a clinical trial is reported; no survival or response rates are given because no drug has been studied in this population.
What is missing is any clinical trial testing a drug for this specific EDS subtype. The rarity of the condition — only 42 published cases — makes trial design and patient stratification a fundamental obstacle. Funding for natural history studies and for any drug development effort is absent from the published record.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Clinical Genetics · 2011 · 51 citations · open access
Ehlers–Danlos arthrochalasia type (VIIA–B) – expanding the phenotype: from prenatal life through adulthood
AbstractThe Ehlers-Danlos syndromes (EDS) form a clinically and genetically heterogeneous group of inherited connective-tissue disorders characterized by joint hypermobility, tissue fragility and skin abnormalities. Six subtypes have been well characterized based on clinical features and molecular genetic abnormalities. The arthrochalasia type EDS (formerly types VIIA and B) is characterized by severe generalized joint hypermobility with multiple dislocations including congenital bilateral dislocation of the hips, muscular hypotonia and distinct dysmorphic features. The diagnosis of the arthrochalasia type EDS is of importance in the neonatal period because of consequences of physical disability in later life. However, the differential diagnosis may be difficult because of overlap with other hypermobility syndromes. In addition, the significant hypotonia may direct the physician toward various neuromuscular diagnoses. As patients become older, the hypotonia decreases and facial features become less distinct. In this report, we describe seven patients at different ages. Timing of diagnosis varied from prenatal life to adult age. The diagnosis of EDS type VII was confirmed by biochemical studies or mutation analysis showing characteristic mutations in COL1A1 and COL1A2. These mutations result in skipping of exon 6, which leads to defective collagen synthesis. For physicians treating patients with EDS type VII, achieving mobility for the patient is the greatest challenge and it may be impossible because of recurrent dislocations of nearly all joints in severe cases.
International Journal of Environmental Research and Public Health · 2022 · 12 citations · open access
Ehlers–Danlos Syndrome Type Arthrochalasia: A Systematic Review
AbstractEhlers-Danlos syndrome type arthrochalasia (aEDS) is a rare genetic disease characterized by severe generalized joint hypermobility, bilateral congenital hip dislocation, skin hyperextensibility, muscle hypotonia, and mild dysmorphic features. It is an autosomal dominant connective tissue disease causing defects in collagen, associated with two genes, COL1A1 or COL1A2. Only about 42 cases have been published worldwide. Treatment is currently symptomatic and focuses on increasing the quality of life of these patients, as there is no curative treatment. The main objective of the review was to update information on Ehlers-Danlos syndrome type arthrochalasia from scientific publications. The review report was carried out in accordance with the criteria of the Preferred Reporting Items for Systematic reviews and MetaAnalyses (PRISMA) review protocol, by searching Orphanet, OMIM, PubMed, and Scopus, as well as free sources. A total of 20 articles were analyzed, which, after analysis, provide an updated report that aims to establish a solid starting point for future lines of research.
Asian Journal of Pediatric Research · 2022 · 0 citations · open access
A Case Report on Ehlers Danlos Syndrome
AbstractEhlers-Danlos syndrome (EDS) is a group of hereditary collagen diseases characterized by joint hyperlaxity, skin hyperelasticity, and generalized tissue fragility. We present the case of an 8-year-old child with EDS in its arthrocalasic form type VII, according to the Villefranche classification, who was born to first-cousin parents. There is no curative treatment for EDS, but it is important to make an early diagnosis for optimal symptomatic management of patients and prevention of avoidable complications.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
